Back to search results

Novel DBS Stimulation Patterns for Parkinson's Disease

This study is testing new ways to use Deep Brain Stimulation (DBS) for people with Parkinson's Disease. Specifically, it's looking at "novel DBS stimulation patterns" with the Medtronic Percept PC DBS device. Researchers believe these new patterns might work better and have fewer side effects by targeting specific brain activity. You could be eligible if you are between 19 and 80 years old, have Parkinson's Disease, and have already had bilateral (both sides) STN DBS surgery. The main goal is to see if these new patterns are safe and tolerable over one to two years. The study is currently unclear on its recruitment status and plans to enroll 10 participants.

Study design
This is an open-label, non-randomized study comparing standard and new stimulation patterns in about 10 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for safety and tolerability for one to two years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04799470

Novel DBS Stimulation Patterns for Treatment of Parkinson's Disease

Recruiting
NAAges 19–80InterventionalTreatment
University of Nebraska
~10 participants
Updated 2026-07-22 on ClinicalTrials.gov
What's tested:Novel DBS stimulation patterns

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and Tolerability of novel DBS stimulation patterns.
Measured over Years 1-2

Conditions

Parkinson's Disease

Explore related trials

Parkinson Disease

NCT04799470

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Unversity of Nebraska Medical Center

    Omaha, Nebraskastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Aviva Abosch, MD, PhD · PRINCIPAL_INVESTIGATOR · University of Nebraska

Who to contact

Dulce Maroni, PhD
[email protected]
402-215-3053
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients have been previously implanted with bilateral STN DBS and the Medtronic Percept PC implantable neural stimulator.
Patients are optimized for clinical stimulation and medication for at least 3 months post-surgery for the implantation of their DBS system.
Consent to study participation
Presence of a robust beta peak (detectable using the Percept BrainSense Survey feature; ≥ 0.7 µV/rtHz), intra-operatively (assessed via Lead Confirm technology from Alpha Omega)
Good response to stimulation (30% improvement on UPDRS III compared to baseline OFF), at least 3 months post-surgery.

Exclusion

Not currently implanted with the Medtronic Percept INS
Not willing to participate in the study
Unstable stimulation with need for frequent reprogramming or further adjustment
Significant stimulation-induced side effects
Need for unusual programming parameters such as very high (\> 200 Hz) or low (\< 100) frequencies (due to cycle limitations)
The patient has an implanted cardiac device
The patients Medtronic Percept TM PC indicates elective-replacement-indicated (ERI) at the start of the study

What this trial measures

  • Safety and Tolerability of novel DBS stimulation patterns.Years 1-2

    To assess if the novel stimulation patterns provide similar side effect profile, when compared to standard clinical stimulation, tolerability will be assessed by: 1. Number of study participants experiencing stimulation-related side effects. Side effects will be measured as patient-reported severity and type of side effect. 2. Number of study participants experiencing stimulation-related Adverse Events.